April 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

April 2007

Pharmaceutical Technology


Companies receiving the Feb. 26 Warning Letters are Actavis Totowa LLC; Anabolic Laboratories; Bio Pharm Inc.; Breckenridge Pharmaceutical Inc.; Centrix Pharmaceutical Inc.; DRX Pharmaceutical Consultants Inc.; DSC Laboratories; Excellium Pharmaceutical Inc.; Ferndale Laboratories, Inc.; IVAX Pharmaceuticals Inc. (formerly Goldline Laboratories Inc.); Kaiser Foundation Hospitals; Lini Inc.; Murfreesboro Pharmaceutical Nursing Supply; Nucare Pharmaceuticals, Inc.; Qualitest Pharmaceuticals, Inc; Sandoz, Inc.; The Harvard Drug Group LLC (formerly Major Pharmaceuticals Inc.); United Research Laboratories Inc. and Mutual Pharmaceutical Company; and Vintage Pharmaceuticals Inc.
-Maribel Rios

RESTRUCTURING

Bayer HealthCare Plans 6100 Job Cuts Worldwide

Berlin (Mar. 2)—Estimating it would save approximately EUR 700 million ($918 million), Bayer HealthCare ( http://www.bayerhealthcare.com/) will integrate the activities of its Pharma division with those of the former Schering AG, Germany. The company confirmed the action would eliminate nearly 6100 jobs worldwide, including 1000 in the United States and 3150 in Europe. Some 1850 production positions and 1400 global research and development functions will be cut by 2009.

Bayer Healthcare officials state the action is intended to "create slimmed-down and efficient structures and do away with double functions and overlaps."

"We said right from the start of the integration that job cuts would be necessary in order to achieve the synergy targets," said Werner Wenning, chairman of the Bayer AG Group Management Board and the Supervisory Board of Bayer Schering Pharma. "These essential streamlining measures are to be fairly implemented in a socially acceptable process, balanced across the globe. This includes the reduction of the number of locations, cutting down on structural and personnel overcapacity, the concentration of research and development activities, as well as the harmonization of structures and processes in marketing and administration."
-Maribel Rios


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here